Cargando…

Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma

BACKGROUND: Polyamines metabolism is closely related to tumor development and progression, as well as tumor microenvironment (TME). In this study, we focused on exploring whether polyamines metabolism-associated genes would provide prognosis and immunotherapy response prediction in lung adenocarcino...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ning, Chai, Mengyu, Zhu, Lingye, Liu, Jingjing, Yu, Chang, Huang, Xiaoying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272553/
https://www.ncbi.nlm.nih.gov/pubmed/37334367
http://dx.doi.org/10.3389/fimmu.2023.1070953
_version_ 1785059521416134656
author Wang, Ning
Chai, Mengyu
Zhu, Lingye
Liu, Jingjing
Yu, Chang
Huang, Xiaoying
author_facet Wang, Ning
Chai, Mengyu
Zhu, Lingye
Liu, Jingjing
Yu, Chang
Huang, Xiaoying
author_sort Wang, Ning
collection PubMed
description BACKGROUND: Polyamines metabolism is closely related to tumor development and progression, as well as tumor microenvironment (TME). In this study, we focused on exploring whether polyamines metabolism-associated genes would provide prognosis and immunotherapy response prediction in lung adenocarcinoma (LUAD). METHODS: The expression profile data of polyamines metabolism-associated genes were acquired from the Cancer Genome Atlas (TCGA) database. Utilizing the least absolute shrinkage and selection operator (LASSO) algorithm, we created a risk score model according to polyamines metabolism-associated gene signatures. Meanwhile, an independent cohort (GSE72094) was employed to validate this model. Through the univariate and multivariate Cox regression analyses, the independent prognostic factors were identified. Subsequently, quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect their expression in LUAD cells. By consensus clustering analysis, polyamines metabolism-associated subgroups were determined in LUAD patients, with differential gene expression, prognosis, and immune characteristics analyses explored. RESULTS: A total of 59 polyamines metabolism genes were collected for this study, of which 14 genes were identified for the construction of risk score model using LASSO method. High- and low- risk groups of LUAD patients in TCGA cohort were distinguished via this model, and high-risk group presented dismal clinical outcomes. The same prognostic prediction of this model had been also validated in GSE72094 cohort. Meanwhile, three independent prognostic factors (PSMC6, SMOX, SMS) were determined for constructing the nomogram, and they were all upregulated in LUAD cells. In addition, two distinct subgroups (C1 and C2) were identified in LUAD patients. Comparing the two subgroups, 291 differentially expressed genes (DEGs) were acquired, mainly enriching in organelle fission, nuclear division, and cell cycle. Comparing to C1 subgroup, the patients in C2 subgroup had favorable clinical outcomes, increased immune cells infiltration, and effective immunotherapy response. CONCLUSION: This study identified polyamines metabolism-associated gene signatures for predicting the patients’ survival, and they were also linked to immune cells infiltration and immunotherapy response in LUAD patients.
format Online
Article
Text
id pubmed-10272553
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102725532023-06-17 Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma Wang, Ning Chai, Mengyu Zhu, Lingye Liu, Jingjing Yu, Chang Huang, Xiaoying Front Immunol Immunology BACKGROUND: Polyamines metabolism is closely related to tumor development and progression, as well as tumor microenvironment (TME). In this study, we focused on exploring whether polyamines metabolism-associated genes would provide prognosis and immunotherapy response prediction in lung adenocarcinoma (LUAD). METHODS: The expression profile data of polyamines metabolism-associated genes were acquired from the Cancer Genome Atlas (TCGA) database. Utilizing the least absolute shrinkage and selection operator (LASSO) algorithm, we created a risk score model according to polyamines metabolism-associated gene signatures. Meanwhile, an independent cohort (GSE72094) was employed to validate this model. Through the univariate and multivariate Cox regression analyses, the independent prognostic factors were identified. Subsequently, quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect their expression in LUAD cells. By consensus clustering analysis, polyamines metabolism-associated subgroups were determined in LUAD patients, with differential gene expression, prognosis, and immune characteristics analyses explored. RESULTS: A total of 59 polyamines metabolism genes were collected for this study, of which 14 genes were identified for the construction of risk score model using LASSO method. High- and low- risk groups of LUAD patients in TCGA cohort were distinguished via this model, and high-risk group presented dismal clinical outcomes. The same prognostic prediction of this model had been also validated in GSE72094 cohort. Meanwhile, three independent prognostic factors (PSMC6, SMOX, SMS) were determined for constructing the nomogram, and they were all upregulated in LUAD cells. In addition, two distinct subgroups (C1 and C2) were identified in LUAD patients. Comparing the two subgroups, 291 differentially expressed genes (DEGs) were acquired, mainly enriching in organelle fission, nuclear division, and cell cycle. Comparing to C1 subgroup, the patients in C2 subgroup had favorable clinical outcomes, increased immune cells infiltration, and effective immunotherapy response. CONCLUSION: This study identified polyamines metabolism-associated gene signatures for predicting the patients’ survival, and they were also linked to immune cells infiltration and immunotherapy response in LUAD patients. Frontiers Media S.A. 2023-06-02 /pmc/articles/PMC10272553/ /pubmed/37334367 http://dx.doi.org/10.3389/fimmu.2023.1070953 Text en Copyright © 2023 Wang, Chai, Zhu, Liu, Yu and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Ning
Chai, Mengyu
Zhu, Lingye
Liu, Jingjing
Yu, Chang
Huang, Xiaoying
Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma
title Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma
title_full Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma
title_fullStr Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma
title_full_unstemmed Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma
title_short Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma
title_sort development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272553/
https://www.ncbi.nlm.nih.gov/pubmed/37334367
http://dx.doi.org/10.3389/fimmu.2023.1070953
work_keys_str_mv AT wangning developmentandvalidationofpolyaminesmetabolismassociatedgenesignaturestopredictprognosisandimmunotherapyresponseinlungadenocarcinoma
AT chaimengyu developmentandvalidationofpolyaminesmetabolismassociatedgenesignaturestopredictprognosisandimmunotherapyresponseinlungadenocarcinoma
AT zhulingye developmentandvalidationofpolyaminesmetabolismassociatedgenesignaturestopredictprognosisandimmunotherapyresponseinlungadenocarcinoma
AT liujingjing developmentandvalidationofpolyaminesmetabolismassociatedgenesignaturestopredictprognosisandimmunotherapyresponseinlungadenocarcinoma
AT yuchang developmentandvalidationofpolyaminesmetabolismassociatedgenesignaturestopredictprognosisandimmunotherapyresponseinlungadenocarcinoma
AT huangxiaoying developmentandvalidationofpolyaminesmetabolismassociatedgenesignaturestopredictprognosisandimmunotherapyresponseinlungadenocarcinoma